Carbamylated erythropoietin is neuroprotective in an experimental model of traumatic brain injury - PubMed (original) (raw)
Carbamylated erythropoietin is neuroprotective in an experimental model of traumatic brain injury
Chiara Adembri et al. Crit Care Med. 2008 Mar.
Abstract
Objective: The well-documented neuroprotective effects of recombinant human erythropoietin (rhEPO) are commonly associated with untoward erythrocyte-stimulating effects (polycythemia), with subsequent risk of thromboembolic complications. A carbamylated-rhEPO (CEPO) derivative, which is neuroprotective but lacks hematopoietic activity, has been recently developed. In this study, we evaluated the neuroprotective capability of CEPO in an in vitro model of cerebral trauma in which rhEPO was previously shown to reduce posttraumatic cell death.
Design: Prospective, controlled experiment.
Setting: Animal, basic science laboratory.
Subjects: Wistar rats, 8 days old.
Interventions: Organotypic hippocampal slices, obtained from rat brains, were subjected to a well-characterized model of mechanical injury followed by addition of 10 IU/mL rhEPO, 10-100 IU/mL CEPO, or vehicle (injured control) to the incubation medium at different times to assess the temporal window of therapeutic neuroprotection.
Measurements and main results: Posttraumatic cell death was quantified at 12, 24, or 48 hrs after injury by measuring propidium iodide fluorescence in the selectively vulnerable CA1 hippocampal area. Posttraumatic injury, observed in injured, vehicle-treated hippocampal slices, was significantly attenuated by addition of either 10 IU/mL rhEPO or 10 IU/mL CEPO. The neuroprotective efficacy of 10 IU/mL rhEPO or CEPO remained intact even when administration was delayed 1 hr after trauma. Qualitative microscopy in semithin sections showed that both rhEPO and CEPO exerted a marked pyramidal neuron-sparing effect.
Conclusion: Our study shows that 10 IU/mL CEPO exerts neuroprotective effects comparable with those of rhEPO in an in vitro model of mechanical cerebral trauma. Because CEPO lacks hematopoietic effects and seems to possess a prolonged therapeutic time window, this erythropoietin derivative may represent an exciting new pharmacologic tool in treating patients with mechanical injury to the brain.
Similar articles
- Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: a potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO).
Chen G, Shi JX, Hang CH, Xie W, Liu J, Liu X. Chen G, et al. Neurosci Lett. 2007 Oct 2;425(3):177-82. doi: 10.1016/j.neulet.2007.08.022. Epub 2007 Aug 19. Neurosci Lett. 2007. PMID: 17825990 - Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat.
King VR, Averill SA, Hewazy D, Priestley JV, Torup L, Michael-Titus AT. King VR, et al. Eur J Neurosci. 2007 Jul;26(1):90-100. doi: 10.1111/j.1460-9568.2007.05635.x. Eur J Neurosci. 2007. PMID: 17614942 - Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen-glucose deprivation (OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures.
Montero M, Poulsen FR, Noraberg J, Kirkeby A, van Beek J, Leist M, Zimmer J. Montero M, et al. Exp Neurol. 2007 Mar;204(1):106-17. doi: 10.1016/j.expneurol.2006.09.026. Epub 2006 Dec 8. Exp Neurol. 2007. PMID: 17157835 - The use of erythropoietin and its derivatives to treat spinal cord injury.
Mofidi A, Bader A, Pavlica S. Mofidi A, et al. Mini Rev Med Chem. 2011 Aug;11(9):763-70. doi: 10.2174/138955711796355267. Mini Rev Med Chem. 2011. PMID: 21707531 Review. - Cellular protection by erythropoietin: new therapeutic implications?
Joyeux-Faure M. Joyeux-Faure M. J Pharmacol Exp Ther. 2007 Dec;323(3):759-62. doi: 10.1124/jpet.107.127357. Epub 2007 Aug 23. J Pharmacol Exp Ther. 2007. PMID: 17717190 Review.
Cited by
- A novel organotypic cortical slice culture model for traumatic brain injury: molecular changes induced by injury and mesenchymal stromal cell secretome treatment.
Pischiutta F, Cavaleiro H, Caruso E, Tribuzio F, Di Marzo N, Moro F, Kobeissy F, Wang KK, Salgado AJ, Zanier ER. Pischiutta F, et al. Front Cell Neurosci. 2023 Jul 18;17:1217987. doi: 10.3389/fncel.2023.1217987. eCollection 2023. Front Cell Neurosci. 2023. PMID: 37534042 Free PMC article. - Carbamoylated Erythropoietin-Induced Cerebral Blood Perfusion and Vascular Gene Regulation.
Sadanandan J, Sathyanesan M, Liu Y, Tiwari NK, Newton SS. Sadanandan J, et al. Int J Mol Sci. 2023 Jul 15;24(14):11507. doi: 10.3390/ijms241411507. Int J Mol Sci. 2023. PMID: 37511274 Free PMC article. - Effect of carbamylated erythropoietin on neuronal apoptosis in fetal rats during intrauterine hypoxic-ischemic encephalopathy.
Diao M, Qu Y, Liu H, Ma Y, Lin X. Diao M, et al. Biol Res. 2019 May 13;52(1):28. doi: 10.1186/s40659-019-0234-7. Biol Res. 2019. PMID: 31084604 Free PMC article. - The role of TAM family receptors and ligands in the nervous system: From development to pathobiology.
Shafit-Zagardo B, Gruber RC, DuBois JC. Shafit-Zagardo B, et al. Pharmacol Ther. 2018 Aug;188:97-117. doi: 10.1016/j.pharmthera.2018.03.002. Epub 2018 Mar 4. Pharmacol Ther. 2018. PMID: 29514053 Free PMC article. Review. - Neuroprotection and CD131/GDNF/AKT Pathway of Carbamylated Erythropoietin in Hypoxic Neurons.
Ding J, Wang J, Li QY, Yu JZ, Ma CG, Wang X, Lu CZ, Xiao BG. Ding J, et al. Mol Neurobiol. 2017 Sep;54(7):5051-5060. doi: 10.1007/s12035-016-0022-0. Epub 2016 Aug 19. Mol Neurobiol. 2017. PMID: 27541284
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous